Pages that link to "Q81381423"

The following pages link to Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease (Q81381423):

Displaying 39 items.

• B cells in chronic graft-versus-host disease (Q26861706) (← links)
• Fibrotic and sclerotic manifestations of chronic graft-versus-host disease (Q27024147) (← links)
• The Role of Animal Models in the Study of Hematopoietic Stem Cell Transplantation and GvHD: A Historical Overview (Q28066083) (← links)
• Treatment of refractory chronic GVHD with rituximab: a GITMO study. (Q33375484) (← links)
• Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease (Q33385079) (← links)
• Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study (Q33588875) (← links)
• High levels of B-cell activating factor in patients with active chronic graft-versus-host disease (Q34135089) (← links)
• Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study (Q34255166) (← links)
• Rituximab for steroid-refractory chronic graft-versus-host disease (Q35848933) (← links)
• Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease (Q35930604) (← links)
• Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation (Q35970489) (← links)
• Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. (Q36264895) (← links)
• Oral graft-versus-host disease. (Q36932886) (← links)
• Rippled skin, fasciitis, and joint contractures (Q36991852) (← links)
• Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease. (Q37104281) (← links)
• Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial (Q37113099) (← links)
• Therapy of chronic graft-versus-host disease (Q37173479) (← links)
• The role of rituximab in autologous and allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma (Q37738413) (← links)
• Rituximab: a review of dermatological applications (Q37781697) (← links)
• Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins (Q37810286) (← links)
• Rituximab for prevention and treatment of graft-versus-host disease (Q37872661) (← links)
• B cell homeostasis and the development of chronic graft-versus-host disease: implications for B cell-depleting therapy (Q37899200) (← links)
• Graft-versus-host disease: part II. Management of cutaneous graft-versus-host disease (Q37993979) (← links)
• Prophylactic and therapeutic treatment of graft-versus-host disease in Japan (Q38416371) (← links)
• Diagnosis and Management of Systemic Sclerosis: A Practical Approach. (Q38667111) (← links)
• Impact of Immune-Modulatory Drugs on Regulatory T Cell (Q38918124) (← links)
• Towards a rational graft-versus-host disease (GVHD) prophylaxis: rituximab should not be forgotten (Q40892130) (← links)
• RETRACTED ARTICLE: Cotransplantation of human umbilical cord mesenchymal and haplo-hematopoietic stem cells in patients with severe aplastic anemia (Q41376484) (← links)
• Current perspective on rituximab in rheumatic diseases (Q42373160) (← links)
• Clinical evaluation of haploidentical hematopoietic combined with human umbilical cord-derived mesenchymal stem cells in severe aplastic anemia. (Q52680964) (← links)
• Monitoring the kinetics of B-cell recovery following rituximab may guide the management of steroid-refractory chronic GvHD. (Q52897641) (← links)
• The Role of B Cell Targeting in Chronic Graft-Versus-Host Disease. (Q52971841) (← links)
• Tirosin Kinase Inhibitors in Chronic Graft versus Host Disease: From Bench to Bedside (Q54546815) (← links)
• [Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab] (Q80516806) (← links)
• Rituximab as salvage therapy for refractory chronic GVHD (Q80709875) (← links)
• Relapse of preB-ALL after rituximab treatment for chronic graft versus host disease: implications for its use? (Q81303697) (← links)
• Lack of efficacy of rituximab in refractory sclerodermatous chronic GVHD (Q84589663) (← links)
• Safety and efficacy of rituximab-based first line treatment of chronic GVHD (Q90289034) (← links)
• Anti-Ro52 Autoantibodies Are Related to Chronic Graft-vs.-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation (Q98735455) (← links)